AACI Update | October 2021

Headlines

Annual Meeting Spotlight: The National Cancer Act at 50

The 2021 AACI/CCAF Annual Meeting will virtually convene AACI cancer center members with national cancer research and advocacy groups, industry, and government health agencies on October 19-21. In honor of the 50th anniversary of the National Cancer Act (NCA), one meeting session will examine the last 50 years of progress and potential for the future.

AACI Committees Welcome New Members, Invite Nominations

This fall, AACI will welcome new members to its Clinical Research Innovation (CRI) Steering Committee. The new members will formally assume their duties during the 2021 AACI/CCAF Annual Meeting, held virtually October 19-21. AACI is also seeking nominations for new members to join the Physician Clinical Research (PCLI) Steering Committee.

Community Outreach and Engagement Listserv Launched

AACI recently launched a listserv for community outreach and engagement professionals at AACI cancer centers. The purpose of the listserv is to provide a platform for members to ask questions or reach out to others about COE-related topics.

Patient Resource Navigator: A System Solution to Guiding Each Patient's Journey

"These guides build bi-directional communication between our providers and their patients. We’ve seen an increase in patient retention and overall patient satisfaction." - Terry T. Tsue, MD, FACS, Vice President and Physician-in-Chief, The University of Kansas Cancer Center; Vice President of Physician Services, The University of Kansas Health System

For more information, please contact Amy Galey.

Learn More

Transforming Cancer Care

Last month, AACI partnered with Mediaplanet on its Transforming Cancer Care campaign, highlighting the ways in which the health care community is advancing equitable cancer care through innovation and global collaboration. AACI cancer centers and sustaining members are among those featured in this special supplement to the September 23 issue of USA TODAY, which also includes a full-page ad from AACI.

News from the Centers

Winkfield Named to National Cancer Advisory Board

Vanderbilt-Ingram Cancer Center

President Joseph Biden has appointed Karen Winkfield, MD, PhD, to the 18-member National Cancer Advisory Board, where she will serve a six-year term helping to guide federal initiatives that focus on cancer.

Rutgers Leader Selected as American Academy of Nursing Fellow

Rutgers Cancer Institute of New Jersey

Carolyn Hayes, PhD, RN, NEA-BC, chief nursing officer for Oncology Services at RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, has been selected by the American Academy of Nursing as a 2021 Fellow.

Friese Appointed to National Cancer Advisory Board

University of Michigan Rogel Cancer Center

President Joseph Biden named Christopher Friese, PhD, RN, among seven new members of the National Cancer Advisory Board. Dr. Friese is associate director for cancer control and population sciences at the University of Michigan Health Rogel Cancer Center. He is a national expert in the analyses of claims data to study care quality and has executed large surveys of ambulatory oncology nurses.

Wilmot Cancer Institute, UR Medicine

Popular Science magazine has named Michael Giacomelli, PhD, a member of the Wilmot Cancer Institute, to its "Brilliant 10" list for 2021. The early-career biomedical engineer, who invented a novel imaging device, joins the magazine’s lineup of the most innovative and creative minds of the year.

Duke Cancer Institute, Duke University Medical Center

The German National Academy of Sciences Leopoldina has elected Joseph Heitman, MD, PhD, chair of the Department of Molecular Genetics and Microbiology at Duke University School of Medicine, and member of Duke Cancer Institute, as one of its members.

Fox Chase Cancer Center, Temple Health

Fox Chase Cancer Center and the Marvin and Concetta Greenberg Pancreatic Cancer Institute were recently renewed as a Clinical Center of Excellence and named for the first time as an Academic Center of Excellence for Pancreatic Cancer by the National Pancreas Foundation.

UAMS Winthrop P. Rockefeller Cancer Institute

The Association of American Medical Colleges (AAMC) recently bestowed the Spencer Foreman Award for Outstanding Community Engagement on the University of Arkansas for Medical Sciences (UAMS). The award is presented annually to an AAMC-member medical school or teaching hospital with a long-standing, major institutional commitment to partnering with the community it serves.

Back to News From the Centers

UVA Earns Comprehensive Cancer Center Designation

University of Virginia Cancer Center

University of Virginia Cancer Center has been awarded a Comprehensive Cancer Center designation effective Feb. 1, 2022, by the National Cancer Institute. The application for the designation required submission of a 1,300-page application, followed by a site visit from 14 distinguished scientists and physicians. Thomas P. Loughran, Jr., MD, is director of the center.

NCI Renews Comprehensive Designation for UNM

University of New Mexico Comprehensive Cancer Center

The University of New Mexico Comprehensive Cancer Center has again been awarded the highest designation and rating in the United States for cancer treatment and research programs by the National Cancer Institute. Its initial designation came in 2005 with renewals in 2010 and 2015. Alan E. Tomkinson, PhD, is the center's interim director.

Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine

Baylor College of Medicine and Stanford University received an award for more than $25 million over five years from the National Institutes of Health to continue building the Clinical Genome (ClinGen) Resource, an effort to create expert curated knowledge about clinically relevant genes and genomic variants for use in precision medicine. The award is one of three NIH grants totaling $73.2 million over five years for the project.

Case Comprehensive Cancer Center

The Case Comprehensive Cancer Center has earned an additional $12 million from the National Cancer Institute as a two-year merit-based extension of its Cancer Center Support Grant. The center is the first of two NCI-Designated Comprehensive Cancer Centers to be awarded this distinction. Stan Gerson, MD, is the center's director.

Stanford Cancer Institute

Crystal Mackall, MD, director of the Stanford Center for Cancer Cell Therapy, was awarded nearly $12 million to investigate whether CAR T cell therapy can be modified to target a brain and spinal cord cancer called diffuse midline glioma.

Duke Cancer Institute, Duke University Medical Center

Duke University is the recipient of two large grants totaling nearly $12 million from the National Human Genome Research Institute as part of its new Impact of Genomic Variation on Function Consortium. The consortium will bring investigators together in a highly collaborative effort to examine how genomes function, how genome function shapes phenotypes, and how these processes are influenced by genomic variation.

Roswell Park Comprehensive Cancer Center

Teams of researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center are combining efforts after together securing a nearly $9 million grant from the National Cancer Institute to develop new and better treatments for ovarian cancer.

$3 Million Grant to Focus on Understanding, Combating Racial Inequities in Lung Cancer

VCU Massey Comprehensive Cancer Center

Virginia Commonwealth University Massey Cancer Center has won a SPORE grant intended to move research findings quickly from the laboratory to patients to address the disproportionate effects of lung cancer on the Black community. The SPORE funding will establish the Translational Research Center in Lung Cancer Disparities. Principal investigator is VCU Massey Director Robert Winn, MD.

Researcher Receives $2.5 Million Grant to Develop Lung Cancer Treatment

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

John Turchi, PhD, a researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, received a five-year, $2.5 million grant from the National Cancer Institute to develop a novel therapy to treat lung cancer.

UCLA Jonsson Comprehensive Cancer Center

Alice Soragni, PhD, has received a $2.5 million grant from the National Cancer Institute to develop lab-grown mini tumors that can help identify treatments for rare types of neuroendocrine cancer. The grant is a joint partnership with Patricia Dahia, MD, PhD, of the University of Texas Health Science Center at San Antonio.

Huntsman Cancer Institute at the University of Utah

Huntsman Cancer Institute predoctoral fellow Prasoona Karra, MS, was selected to receive the National Cancer Institute (NCI) Predoctoral to Postdoctoral Fellow Transition Award. These awards are presented to “outstanding predoctoral researchers” and are designed to support them in the late stages of PhD training through transition to postdoctoral position. The award provides up to six years of funding.

Baumann Receives Clinical Investigator Award

Siteman Cancer Center

Brian C. Baumann, MD, a radiation oncologist at Siteman Cancer Center, has been awarded a 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.

Vanderbilt-Ingram Cancer Center

The Meharry Medical College/Vanderbilt-Ingram Cancer Center/Tennessee State University Partnership (MVTCP) has received renewed funding for the next five years to continue collaborations to eliminate cancer health disparities. Entering its 22nd consecutive year of funding, the MVTCP is the longest-standing partnership supported through the National Cancer Institute's U54 Comprehensive Partnerships to Advance Cancer Health Equity program.

Back to News From the Centers

Colorectal Surgeon Joins Cancer Team

UMMC Cancer Center and Research Institute

Kelly Brister, MD, a colorectal surgeon, has joined the University of Mississippi Medical Center Interdisciplinary Gastrointestinal Cancer Team. She will provide care to a population with one of the lowest colorectal cancer screening rates in the nation.

VCU Massey Comprehensive Cancer Center

For the last 17 years, Emmanuel A. Taylor, MSc, DrPH, served as health scientist administrator and program director in the Office of the Director of the Center to Reduce Cancer Health Disparities at the National Cancer Institute. He now joins Virginia Commonwealth University as a researcher at Massey Cancer Center.

Tempera Appointed Associate Director for Cancer Research Career Enhancement

Ellen and Ronald Caplan Cancer Center of The Wistar Institute

The Wistar Institute announces the appointment of Italo Tempera, PhD, as associate director for cancer research career enhancement at the institute’s cancer center. In this role, Dr. Tempera will lead the educational mission of the institute and its cancer center to train scientists and create workforce development programs in the life sciences.

Brown Center for Immunotherapy Names Inaugural Executive Director

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indiana University School of Medicine has named its first executive director of the Brown Center for Immunotherapy. Huda Salman, MD, PhD, will become the center’s new leader, effective November 1. She joins IU School of Medicine from Stony Brook Cancer Center, where she directs the CAR T-cell program.

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Neurosurgical oncologist, Amy Heimberger, MD, has joined the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as the Jean Malnati Miller Professor of Brain Tumor Research and scientific director of the Lou and Jean Malnati Brain Tumor Institute of the Lurie Cancer Center.

Molina Named AD for Community Outreach and Engagement

University of Illinois Cancer Center

Yamilé Molina, PhD, MPH, MS, has been named associate director for community outreach and engagement for the University of Illinois Cancer Center. She takes the helm from Karriem Watson, DHSc, MS, MPH, as he transitions to a new leadership role as chief engagement officer for the All of Us research initiative at the National Institutes of Health.

New Chief of Thoracic and Head and Neck Medical Oncology Named

Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health welcome Missak Haigentz, Jr., MD, as chief of Thoracic and Head and Neck Medical Oncology and clinical director for Oncology Integration.

Masonic Cancer Center, University of Minnesota

Aaron Schilz, MPA, has been appointed as the interim executive director for the Masonic Cancer Center. He assumes the position previously held by Seanne Falconer, MBA, FACHE, who has accepted the role of executive director, administration at the Moores Cancer Center at UC San Diego Health.

Ellen and Ronald Caplan Cancer Center of The Wistar Institute

The Wistar Institute welcomes Amelia Escolano, PhD, and Nan Zhang, PhD, as assistant professors. Dr. Escolano’s research focuses on the development of novel vaccine approaches against highly mutating viruses. Dr. Zhang studies the role of a group of white blood cells known as macrophages during ovarian cancer metastasis in the abdominal cavity.

Roswell Park Comprehensive Cancer Center

Carl Morrison, MD, DVM, has been promoted to chair of pathology and laboratory medicine. Dr. Morrison, who joined Roswell Park in 2007, remains senior vice president for scientific development and integrative medicine.

Associate Director for Translational Research Named

Masonic Cancer Center, University of Minnesota

Emmanuel S. Antonarakis, MD, has joined the University of Minnesota Medical School faculty as associate director for translational research at Masonic Cancer Center. He succeeds Jill Siegfried, PhD. Dr. Antonarakis will also serve as director of genitourinary oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation of the U of M Medical School.

UMMC Cancer Center and Research Institute

Carolann Risley, PhD, MSN, recently returned to the University of Mississippi Medical Center as an associate professor of nursing and member of the UMMC Cancer Center and Research Institute. She has focused on research into the basis for racial disparities in cervical cancer since she was a UMMC graduate student.

Back to News From the Centers

Investigators Uncover Cellular Pathway Involved in Cancer Growth

Cedars-Sinai Cancer

Cedars-Sinai Cancer investigators have found a potential way to block the functioning of a gene mutation that promotes cancer immortality and growth in 70 percent of bladder cancer patients. This discovery may lead to an effective therapy for cancer patients with the mutation, while reducing side effects to normal cells and tissues. Dan Theodorescu, MD, PhD, is director of Cedars-Sinai Cancer and the corresponding author for the study.

Huntsman Cancer Institute at the University of Utah

Cells have quality controls, or checkpoints, to keep mistakes from happening. One of the last steps in cell division is a quality control process called the abscission checkpoint. If that checkpoint doesn’t work, cells divide even with mistakes present. This contributes to a higher risk of several kinds of cancer. Collaborative research from labs at Huntsman Cancer Institute looks at how the abscission checkpoint functions.

The University of Texas MD Anderson Cancer Center

A new discovery from researchers at The University of Texas MD Anderson Cancer Center has clarified the long-established connection between inflammation and pancreatic cancer development. According to the study, pancreatic cells display an adaptive response to repeated inflammatory episodes that initially protects against tissue damage but can promote tumor formation in the presence of mutant KRAS.

The University of Kansas Cancer Center

The University of Kansas Cancer Center was invited to participate in a national pilot project being conducted by the American Society of Clinical Oncology and the Association of Community Cancer Centers. The pilot project is testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among cancer treatment trial participants.

University of Illinois Cancer Center

University of Illinois Cancer Center researchers have discovered a potential drug target for treating aggressive pancreatic cancer. Their findings showed that an experimental compound inhibited pancreatic cancer in mice, significantly extending their survival and reducing tumor growth in a mouse model of pancreatic ductal adenocarcinoma.

Siteman Cancer Center

Blood and urine tests could lead to faster and less invasive methods to diagnose and monitor various types of tumors, according to new research from Washington University scientists at Siteman Cancer Center. Two studies describe the potential of liquid biopsies to identify and track tumor growth in bladder cancer and peripheral nerve tumors.

Sidney Kimmel Cancer Center at Jefferson Health

Tebentafusp, an investigational bispecific fusion protein, significantly improves overall survival among patients with metastatic uveal melanoma, according to results from a multicenter, randomized, Phase III clinical trial.

Fred Hutchinson Cancer Center

A new computational method called CoNGA could help bring into focus the hidden biological patterns that link T-cell receptor, or TCR, gene sequences and T-cell function.

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

A study at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute turns cancer scientists into molecular detectives, searching for clues for why certain cancers are able to spread and evolve by studying tissues collected within hours of death. The Rapid Cancer Research Autopsy Trial allows scientists to gather biological samples after a patient’s death to conduct research otherwise not possible.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

A large international collaboration led by researchers from the Johns Hopkins Kimmel Cancer Center has identified promising new targets for pancreatic cancer treatment and early diagnosis after examining various aspects of these tumors’ genes and proteins.

UCSF Helen Diller Family Comprehensive Cancer Center

UCSF researchers discover a new role for Erα as an RNA-binding protein, offering clues to overcoming resistance to therapies like tamoxifen that are used in many types of breast cancer.

Cedars-Sinai Cancer

Cedars-Sinai Cancer researchers have created a new system for classifying melanoma when the disease has spread to the lymph nodes. This system may offer a better tool for predicting patients' outcomes and determining their treatment needs.

The University of Arizona Cancer Center

The University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.

USC Norris Comprehensive Cancer Center

New research reveals children born with a genetic predisposition to produce more lymphocytes, particularly in relation to other types of white blood cells, are at a higher risk of developing acute lymphoblastic leukemia.

UK Markey Cancer Center

A new study from UK Markey Cancer Center researchers demonstrate a combination of two drugs may be useful to treat ovarian cancers that are resistant to paclitaxel.

Wilmot Cancer Institute, UR Medicine

Individuals diagnosed with intrahepatic cholangiocarcinoma, a type of liver cancer, face a five-year survival rate of less than 10 percent. But a Wilmot Cancer Institute team that also investigates pancreatic cancer, which has similarly poor survival statistics, discovered factors that both aggressive cancers have in common.

University of Michigan Rogel Cancer Center

Communication between patients and their primary care providers is key to ensuring effective cancer care, both before diagnosis and after treatment, according to two recent papers led by University of Michigan Rogel Cancer Center researchers.

The University of Texas MD Anderson Cancer Center

A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

Case Comprehensive Cancer Center

Researchers from the Case Comprehensive Cancer Center have uncovered the potentially important role of the protein-coding gene, MYO10, in tumor development and immune therapy response.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

In human cancer cell and mouse studies, researchers from Johns Hopkins Medicine have found that a set of proteins work in tandem to build supply lines that deliver oxygen and nutrients to tumors, enabling them to survive and grow.

Stanford Cancer Institute

In a recent study, a team of Stanford researchers identified hundreds of potential targets for cancer therapies using a new screening strategy that allows for the systematic activation and deactivation of thousands of genes in both cancer cells and immune cells.

Sidney Kimmel Cancer Center at Jefferson Health

Video-based education is an acceptable pretesting alternative to traditional consultations with a genetic counselor for many men with prostate cancer or at-risk for prostate cancer who have been referred for genetic testing, according to results from the Evaluation and Management for Prostate Oncology, Wellness, and Risk study from researchers at the Sidney Kimmel Cancer Center at Jefferson Health.

Back to News From the Centers

UCSF Selected for ASCO Mentor Program

UCSF Helen Diller Family Comprehensive Cancer Center

Under the leadership of Ana Velázquez Mañana, MD, fellow in medical oncology, UCSF, was chosen as one of only five institutions nationwide to participate in the American Society of Clinical Oncology's (ASCO) inaugural Oncology Summer Internship program to increase diversity in the oncology workforce.

The University of Kansas Cancer Center

National Cancer Institute Director Ned Sharpless, MD, and Office of Cancer Centers Director Henry Ciolino, PhD, joined Roy Jensen, MD, director of The University of Kansas Cancer Center, for a special episode of the center’s Facebook Live series "Bench to Bedside" on September 29 to discuss the 50th anniversary commemoration of the National Cancer Act, as well as the latest in cancer research, the impact of the COVID-19 pandemic on cancer research, and the NCI’s health equity efforts.

Cancer Clinical Trials Exclude Too Many Patients: That is Changing

Fred Hutchinson Cancer Center

A new study by Joseph Unger, PhD, MS, of Fred Hutchinson Cancer Research Center, showed there was little evidence of enrollment reductions to treatment trials during the entire first year of the pandemic. Rather, it’s the eligibility criteria that keeps most cancer patients out of trials.

The University of Arizona Cancer Center

An enzyme with an elusive role in severe inflammation may be a key mechanism driving COVID-19 severity and could provide a new therapeutic target to reduce COVID-19 mortality, according to a study by researchers from the University of Arizona, in collaboration with Stony Brook University and Wake Forest School of Medicine.

Back to News From the Centers

Meeting Announcements

CURE Distinguished Scholars Seminar: Structure, Trust and Science

October 14, 2021

1:00 PM - 2:30 PM

WebEx Seminar

The NCI Center to Reduce Cancer Health Disparities (CRCHD) is pleased to invite you to join the upcoming Continuing Umbrella of Research Experiences (CURE) Distinguished Scholars Seminar at 1:00 pm eastern time on Thursday, October 14.

The next lecture in the CURE DSS Series will be presented by VCU Massey Cancer Center Director Robert A. Winn, MD, who is the second-ever African American director of an NCI-Designated Cancer Center.

The CURE Program supports individuals from underrepresented groups across the academic continuum—beginning with middle school students and continuing through independent cancer researchers—through a pipeline of research funding opportunities.

For more information about this seminar, please contact Victoria Coan.

If you are an individual with a disability who needs reasonable accommodations to participate in this event, please contact Victoria Coan ([email protected] or 240-276-7659) at least two business days before the event, so that we can discuss your accommodation request.

Learn More

2021 AACI/CCAF Annual Meeting

October 19, 2021

Virtual Meeting

This three-day event convenes AACI cancer center members with national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges. No other program presents information on cancer research and patient care issues as they pertain to the leaders of the nation's cancer centers and provides those leaders with a forum to discuss common issues with their peers.

Continuing Medical Education (CME) is jointly provided by the American Association for Cancer Research (AACR) and AACI.

Learn More and Register

Artificial Intelligence in Oncology Symposium

November 8, 2021

Case Comprehensive Cancer Center

The 2021 Artificial Intelligence in Oncology Symposium: Precision Medicine and Cancer Disparities will bring together experts in AI and machine learning as well as clinical, industry, and federal agency experts in pathology, radiology, drug discovery, ethics, and policy to speak on research developments, regulatory policy, reimbursement, and ethics surrounding AI in oncology. For the health and safety of all attendees, this year's symposium will again take place virtually.

Registration for the symposium is not yet open.

Sign up to receive updates.

Learn More

14th Annual AACI CRI Meeting

July 12, 2022

Loews Chicago O'Hare Hotel, 5300 N. River Rd., Rosemont, IL 60018

The AACI Clinical Research Innovation (CRI) program serves as a network for research leaders to develop and share best practices for the efficient operation of clinical trials offices (CTO) at AACI cancer centers. The programming of the 14th Annual AACI CRI Meeting, “Partnering in Progress,” aligns with CRI's strategic goal of stimulating cancer center interactions to maximize resources by creating opportunities for peer-to-peer networking and collaboration.

The health and safety of meeting attendees is of paramount importance. AACI continues to closely monitor the COVID-19 pandemic and related public health guidelines. We are currently planning for an in-person event and will implement protective measures in accordance with current guidelines from the Centers for Disease Control and Prevention (CDC) and the City of Chicago. A virtual option is available to those unable to attend in person.

Please visit the meeting website for more information on COVID-19 masking, vaccination, and testing policies:
Health and Safety Measures
FAQ

AACI reserves the right to revise vaccination, masking, and testing policies based on evolving public health recommendations, and will notify attendees of any changes as soon as possible.

Learn More

2022 AACI/CCAF Annual Meeting

October 2, 2022

InterContinental at the Plaza, 401 Ward Pkwy., Kansas City, MO 64112

AACI cancer centers form North America's cancer research infrastructure and are hubs of critical discoveries, treatment advances and improvements in patient care. AACI and the Cancer Center Administrators Forum (CCAF) jointly formulated the program for the 2022 AACI/CCAF Annual Meeting.

This three-day event convenes AACI cancer center members with national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges. No other program presents information on cancer research and patient care issues as they pertain to the leaders of the nation's cancer centers and provides those leaders with a forum to discuss common issues with their peers.

Continuing Medical Education (CME) is jointly provided by the American Association for Cancer Research (AACR) and AACI. Your participation in this national meeting helps us chart a course for AACI's work on behalf of its cancer center network. We look forward to hosting you and your colleagues for this always innovative and high-quality educational experience.

Learn More

AACI Update | October 2021

Headlines

Annual Meeting Spotlight: The National Cancer Act at 50

AACI Committees Welcome New Members, Invite Nominations

Community Outreach and Engagement Listserv Launched

Patient Resource Navigator: A System Solution to Guiding Each Patient's Journey

Transforming Cancer Care

News from the Centers

Winkfield Named to National Cancer Advisory Board

Vanderbilt-Ingram Cancer Center

Rutgers Leader Selected as American Academy of Nursing Fellow

Rutgers Cancer Institute of New Jersey

Friese Appointed to National Cancer Advisory Board

University of Michigan Rogel Cancer Center

Researcher Makes List of Game Changers

Wilmot Cancer Institute, UR Medicine

Heitman Elected to German Academy

Duke Cancer Institute, Duke University Medical Center

Pancreatic Cancer Center of Excellence Designations Announced

Fox Chase Cancer Center, Temple Health

UAMS Wins AAMC Award for Outstanding Community Engagement

UAMS Winthrop P. Rockefeller Cancer Institute

UVA Earns Comprehensive Cancer Center Designation

University of Virginia Cancer Center

NCI Renews Comprehensive Designation for UNM

University of New Mexico Comprehensive Cancer Center

Baylor Awarded NIH Funding for Clinical Genome Resource

Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine

Case Receives Merit Extension From NCI

Case Comprehensive Cancer Center

Grant Awarded for Clinical Trial to Treat Brain Cancer

Stanford Cancer Institute

Two New NIH-Funded Centers to Explore Impacts of Genomic Variation in Health, Disease

Duke Cancer Institute, Duke University Medical Center

Nearly $9 Million Awarded for Ovarian Cancer Research

Roswell Park Comprehensive Cancer Center

$3 Million Grant to Focus on Understanding, Combating Racial Inequities in Lung Cancer

VCU Massey Comprehensive Cancer Center

Researcher Receives $2.5 Million Grant to Develop Lung Cancer Treatment

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

$2.5 Million Grant to Help Develop Lab-Grown Mini Tumors for Rare Tumors

UCLA Jonsson Comprehensive Cancer Center

Trainee Receives NCI Award

Huntsman Cancer Institute at the University of Utah

Baumann Receives Clinical Investigator Award

Siteman Cancer Center

Funding Renewed for Cancer Disparities Partnership

Vanderbilt-Ingram Cancer Center

Colorectal Surgeon Joins Cancer Team

UMMC Cancer Center and Research Institute

Epidemiologist Joins Massey

VCU Massey Comprehensive Cancer Center

Tempera Appointed Associate Director for Cancer Research Career Enhancement

Ellen and Ronald Caplan Cancer Center of The Wistar Institute

Brown Center for Immunotherapy Names Inaugural Executive Director

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Neurosurgical Oncologist Joins Lurie

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Molina Named AD for Community Outreach and Engagement

University of Illinois Cancer Center

New Chief of Thoracic and Head and Neck Medical Oncology Named

Rutgers Cancer Institute of New Jersey

Schilz Named Interim Executive Director

Masonic Cancer Center, University of Minnesota

Vaccine Researcher, Immunologist Recruited as Assistant Professors

Ellen and Ronald Caplan Cancer Center of The Wistar Institute

Precision Medicine Pioneer Named Chair of Pathology

Roswell Park Comprehensive Cancer Center

Associate Director for Translational Research Named

Masonic Cancer Center, University of Minnesota

Risley Returns to UMMC

UMMC Cancer Center and Research Institute

Investigators Uncover Cellular Pathway Involved in Cancer Growth

Cedars-Sinai Cancer

Lab Finding May Broaden Understanding of How Some Cancers Begin

Huntsman Cancer Institute at the University of Utah

Link Between Inflammation and Pancreatic Cancer Development Uncovered

The University of Texas MD Anderson Cancer Center

National Pilot Project to Increase Diversity in Cancer Treatment Trials

The University of Kansas Cancer Center